Risk of stroke during long-term anticoagulant therapy in patients after myocardial infarction

Annals of Neurology

Volumn 39, Issue 3, 1996, Pages 301-307

  Azar, Aida J ^a   Koudstaal, Peter J ^a   Wintzen, Axel R ^b   Van Bergen, Paul F ^a   Jonker, Jan J ^c   Deckers, Jaap W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ASPECT Coordinating Centre   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; PLACEBO;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; BRAIN INFARCTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HEART INFARCTION; HUMAN; LONG TERM EXPOSURE; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; STROKE; SURVIVAL RATE; THROMBOEMBOLISM;

ADULT; AGED; ANTICOAGULANTS; CEREBRAL HEMORRHAGE; CEREBRAL INFARCTION; CEREBROVASCULAR DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLACEBOS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS;

EID: 0029876364     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410390306     Document Type: Article

References (27)

1. Jonker JJC, Chesebro JH. Chronic coronary disease. In: Fuster V, Verstraete M, eds. Thrombosis in cardiovascular disorders. Philadelphia: WB Saunders, 1992:363-374
2. Sixty Plus Reinfarction Study Research Group. Risks of long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Lancet 1982;1:64-68
3. Fogelholm R, Eskola K, Kiminkinen T, Kunnamo I. Anticoagulant treatment as a risk factor for primary intracerebral haemorrhage. J Neurol Neurosurg Psychiatry 1992;55:1121-1124
4. Franke CL, de Jonge H, van Swieten JC, et al. Intracerebral hematomas during anticoagulant treatment. Stroke 1990;21:726-730
5. Foulkes MA, Wolf PA, Price TR. The stroke data bank: design, methods, and baseline characteristics. Stroke 1988;19:547-554
6. Wintzen AR, de Jonge H, Loeliger EA, Bots GTAM. The risk of intracerebral hemorrhage during oral anticoagulant treatment: a population study. Ann Neurol 1984;16:553-558
7. Meade TW, ed. Anticoagulant and myocardial infarction: a reappraisal. New York: John Wiley, 1984
8. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research group. Effect of long-term anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet 1994;1:499-503
9. Sixty Plus Reinfarction Study Research Group. A double-blind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Lancet 1980;2:989-993
10. Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 1990;323:147-152
11. Loeliger EA. The optimal therapeutic range in oral anticoagulation. History and proposal. Thromb Haemost 1979;42:1141-1152
12. Loeliger EA, Broekmans AW. Optimal therapeutic anticoagulation. Haemostasis 1985;15:283-292
13. Loeliger EA, van den Besselaar AMHP, Broekmans AW. Intensity of oral anticoagulation in patients monitored with various thromboplastins. N Engl J Med 1983;1:1228 (Letter)
14. Loeliger EA. Laboratory control, optimal therapeutic ranges and therapeutic quality control in oral anticoagulation. Acta Haematol (Basel) 1985;74:125-131
15. Loeliger EA. Therapeutic target values in oral anticoagulation - justification of Dutch policy and a warning against the so-called moderate-intensity regimens. Ann Hematol 1992;64. 60-65
16. The Ad Hoc Committee on the classification and outline of cerebrovascular disease, II (Chairman CH Milikan). Stroke 1975;6:566-616
17. Cox DR. Regression models and life tables. J R Stat Soc [B] 1972;34:187-220
18. Levine MN, Raskob G, Hirsh J. Hemorrhagic complications of long-term anticoagulant therapy. Chest 1986;89(Suppl):16S-25S
19. Levine MN, Raskob G, Hirsh J. Hemorrhagic complications of long-term anticoagulant therapy. Chest 1989;95(Suppl):26S-36S
20. Landefeld CS, Rosenblatt MW, Goldman L. Bleeding in outpatients treated with warfarin: relation to the prothrombin time and important remediable lesions. Am J Med 1989;87:153-159
21. Launbjerg J, Egeblad H, Heaf J. Bleeding complications to oral anticoagulant therapy: multivariate analysis of 1010 treatment years in 551 outpatients. J Int Med 1991;229:351-355
22. van der Meer FJM, Rosendaal FR, Vandenbroucke JP, Briet E. Bleeding complications in oral anticoagulant therapy: an analysis of risk factors. Arch Intern Med 1993;153:1557-1562
23. Rosendaal FR, Cannegieter SC, van der Meer FJM, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993;69:236-239
24. Azar AJ. Therapeutic achievement with long-term oral anticoagulants in post-myocardial infarction patients. Dissertation, Erasmus University Rotterdam, The Netherlands, 1993
25. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994;308:81-101
26. European Atrial Fibrillation Trial Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischemic attack or minor stroke. Lancet 1993;342:1255-1262
27. Albers GW. Atrial fibrillation and stroke. Arch Intern Med 1994;154:1443-1448